The 21st Annual debra of America Benefit will be held on Monday, October 21, 2019 from 6:00pm to 10:00 pm at Tribeca 360° in New York City. The evening of honors and celebrations will feature cocktails, hors d'oeuvres, a silent auction, and a seated dinner.
Proceeds from the Benefit will go directly towards supporting people living with Epidermolysis Bullosa (EB), a painful, often fatal, and always debilitating rare genetic disease. Click here to learn more.
For questions or for more information about Sponsorship and Ad Opportunities, please contact Nelta Sanon at 212‐868‐1573 x105 or email@example.com.
Click below to see this year's benefit's
exciting new venue!
What is EB?
Epidermolysis Bullosa, or EB, is a rare connective tissue disorder with many genetic and symptomatic variations. All types of EB share the major symptom of extremely fragile skin that blisters and tears from the slightest friction or trauma. Internal organs and bodily systems can also be seriously affected by the disease. EB is always painful, often pervasive and debilitating, and is in some cases lethal before the age of 30. There is currently no cure or treatment for EB. Pain management, wound care, and preventative bandaging are the only options available.
There are about 25,000 people living with EB in the US. It occurs in every racial and ethnic group and affects both genders equally. For a more in-depth and comprehensive understanding of EB, please also check out debra of America’s explanation by clicking here.
What is debra of America?
Because the cost of doing nothing is too great. This axiom defines debra of America's mission and directs all that we do. We are dedicated to improving the quality of life for those living with EB. To achieve our mission, we do two things in parallel: we provide free programs and services to the EB Community in the US, and fund the most innovative research directed at symptom relief and a systemic cure.
In 2017 alone, our largest program, the Wound Care Distribution Program, sent over $1 Million worth of specialized bandages. That translates to over 108,000 pieces of wound care sent to families across the US. Our research funding identified the genetic basis of EB and supports the science, which is at the forefront of gene and stem cell therapy, RNA repair, protein replacement, and inhibition of squamous cell carcinoma.